Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Lisata Therapeutics, Inc. - Common Stock
(NQ:
LSTA
)
2.780
-0.100 (-3.47%)
Streaming Delayed Price
Updated: 1:08 PM EST, Nov 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Lisata Therapeutics, Inc. - Common Stock
Earnings Scheduled For August 14, 2023
August 14, 2023
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.
Via
Benzinga
Earnings Scheduled For November 12, 2024
November 12, 2024
Via
Benzinga
Earnings Outlook For Lisata Therapeutics
November 11, 2024
Via
Benzinga
LSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q2 2024
August 12, 2024
LSTA stock results show that Lisata Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy
July 18, 2024
Haystack Oncology, a Quest Diagnostics company, and Lisata Therapeutics collaborate to use Haystack MRD technology in a study of certepetide plus chemotherapy for metastatic pancreatic cancer, focusing...
Via
Benzinga
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
May 13, 2024
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
Via
News Direct
Exposures
Product Safety
LSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q1 2024
May 09, 2024
LSTA stock results show that Lisata Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Recap: Lisata Therapeutics Q4 Earnings
February 29, 2024
Via
Benzinga
Earnings Scheduled For February 29, 2024
February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via
Benzinga
Lisata Therapeutics's Earnings Outlook
February 28, 2024
Via
Benzinga
Earnings Preview: Lisata Therapeutics
November 01, 2023
Via
Benzinga
Earnings Scheduled For March 30, 2023
March 30, 2023
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
December 13, 2022
On Tuesday, 49 companies hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
December 23, 2022
OnFriday, 143 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
December 14, 2022
On Wednesday, 115 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
October 18, 2022
During Tuesday's session, 78 companies made new 52-week lows.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
September 16, 2022
Via
Benzinga
121 Stocks That Hit Their 52-Week Low
October 14, 2022
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows.
Via
Benzinga
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
September 19, 2022
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
Via
Benzinga
Why NCR Is Trading Lower By Around 23%, Here Are 42 Stocks Moving In Friday's Mid-Day Session
September 16, 2022
Gainers Kensington Capital Acquisition Corp. IV (NYSE: AMPX) jumped 35.4% to $13.54 after gaining 11% on Thursday.
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.